Seltorexant — Safety, Research, Risks & Legal Status

Not medical advice. Seltorexant is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	MIN-202, MIN202, JNJ-42847922, JNJ42847922, JNJ-922, JNJ922
Category	Research Chemical
Drug class	Selective orexin-2 (OX2) receptor antagonist (2-SORA)
Developer	Johnson and Johnson (Janssen) with Minerva Neurosciences
Development codes	MIN-202, JNJ-42847922, JNJ-922
Lead indication	Adjunctive treatment of MDD with insomnia symptoms
Trial stage	Phase 3 (MDD); Phase 2 (insomnia, Alzheimer's disease)
Route / half-life	Oral; short elimination half-life ~2 to 3 hours, CYP3A4-metabolized
US legal status	Seltorexant is an investigational new drug in the United States. It is not FDA-approved for any indication, and it is not a dietary supplement, a food, or a lawful over-the-counter product. It exists only within sponsor-run clinical trials run by Johnson and Johnson (Janssen), with Minerva Neurosciences as a co-developer. There is no legal channel for a consumer to obtain it outside of a trial, and any material sold online as "seltorexant" by a gray-market research-chemical vendor is unverified, outside the regulatory chain of custody, and not approved for human consumption. Unlike the approved dual orexin antagonists suvorexant, lemborexant, and daridorexant, seltorexant carries no prescribing status.

What is Seltorexant?

Seltorexant is an orally administered, selective orexin-2 (OX2) receptor antagonist, a class abbreviated 2-SORA. It is under clinical development primarily as an adjunctive treatment for major depressive disorder (MDD) accompanied by insomnia symptoms, and secondarily has been studied in insomnia and in Alzheimer's disease. It is distinguished from the marketed sleep drugs suvorexant, lemborexant, and daridorexant, which are dual orexin receptor antagonists (DORAs) that block both OX1 and OX2. The proposed rationale is that selectively blocking OX2 may promote sleep and improve mood-related symptoms while sparing some effects attributed to OX1 blockade.

How it works

Orexin (hypocretin) neuropeptides, produced in the lateral hypothalamus, promote wakefulness and arousal by acting at two G-protein-coupled receptors, OX1 and OX2. Seltorexant selectively blocks OX2 with reported greater than 100-fold binding selectivity over OX1, making it a 2-SORA rather than a dual antagonist. OX2 signaling is strongly implicated in maintaining wakefulness, so antagonizing it is proposed to lower arousal and facilitate sleep onset and maintenance. The antidepressant hypothesis is that OX2 blockade may improve mood partly by correcting sleep disturbance and partly through direct effects on limbic and monoaminergic circuits, though the precise mood-relevant mechanism remains proposed rather than proven. Pharmacokinetically the compound is rapidly absorbed (time to peak roughly 0.3 to 1.5 hours) and short-acting (elimination half-life around 2 to 3 hours), and it is metabolized largely by CYP3A4.

Background & history

Seltorexant originated at Janssen (Johnson and Johnson) under the code JNJ-42847922, and was advanced in collaboration with Minerva Neurosciences under the code MIN-202. Early clinical work in the late 2010s established its selective OX2 activity and short half-life and generated proof-of-concept signals in insomnia and in MDD with sleep disturbance. Development then centered on adjunctive treatment of MDD with insomnia symptoms, leading to a Phase 3 program in the 2020s. Positive pivotal data (MDD3001) were reported in 2024, but a later active-comparator Phase 3 study against quetiapine XR (MDD3005), reported around 2025, missed its primary endpoint, leaving the regulatory path uncertain. If approved it would be a first-in-class selective OX2 antagonist.

What the research says

Human data on seltorexant are more mature than for most compounds in this reference, but the overall picture is mixed and the drug remains unapproved. An early proof-of-concept study reported that roughly 10 days of dosing produced a significant improvement in core depressive symptoms versus placebo in MDD, with benefit maintained through about 28 days and accompanied by improvements in sleep-onset and sleep-continuity measures. A pivotal Phase 3 placebo-controlled trial (MDD3001, roughly 588 participants) of seltorexant added to a background antidepressant in MDD with insomnia symptoms was reported in 2024 to meet its primary and key secondary endpoints, showing a statistically significant improvement in the MADRS depression score at day 43 with a favorable tolerability profile. However, a separate Phase 3 head-to-head study (MDD3005) comparing adjunctive seltorexant against quetiapine XR over 26 weeks did NOT meet its primary endpoint: both arms improved depression scores substantially and comparably, and seltorexant showed only a numerically (not statistically) higher response rate, while demonstrating a more favorable metabolic and tolerability profile (less weight gain, lower somnolence). The evidence base is therefore best characterized as promising but not definitive, with efficacy that appears real but modest and dependent on trial design.

Reported effects

Reduced latency to sleep onset (shorter time to fall asleep) reported in insomnia and MDD-with-insomnia populations
Increased total sleep time and improved sleep continuity (reduced wakefulness after sleep onset)
Improvement in core depressive symptoms as an add-on to standard antidepressants in some Phase 3 data (MADRS reduction)
Short duration of action with limited next-day residual sedation reported at studied doses
Improvement in patient-reported sleep-disturbance measures
Sleep-promoting effect achieved without the metabolic and heavy-sedation burden seen with quetiapine in a comparator trial

Dosing & administration (informational)

Informational only, not a protocol and not dosing advice. Published clinical trials have generally studied seltorexant as a single oral dose taken at bedtime, with the 20 mg once-nightly dose featuring prominently in the Phase 3 MDD-with-insomnia program; earlier dose-ranging work explored other levels. These figures describe what appears in the research literature under controlled trial conditions with medical supervision and defined inclusion criteria. They are not a recommendation, do not translate to any gray-market product of unknown content, and should not be used to self-administer. Anyone considering treatment for depression or insomnia should consult a licensed clinician about approved options.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Investigational drug: the full long-term safety profile in unselected populations is not established, and there is no approved-label safety monitoring
Commonly reported adverse effects in trials include somnolence, fatigue, dizziness, headache, abdominal discomfort, and nightmares or abnormal dreams
Orexin-system antagonists as a class carry theoretical concerns about next-day impairment, complex sleep behaviors, and, at higher exposures, cataplexy-like or sleep-paralysis phenomena; whether these apply to seltorexant at studied doses is not fully characterized
As a CNS depressant and sleep-promoting agent it can impair driving and next-morning alertness; combining with alcohol or other sedatives compounds this risk
Gray-market 'research chemical' seltorexant has no verified identity, purity, or dose accuracy, so any self-administration carries unquantifiable contamination and mis-dosing risk
Not studied for safety in pregnancy, lactation, hepatic impairment beyond trial exclusions, or in combination with the many drugs an average person may take
Depression is a serious condition requiring clinical management; self-treating with an unapproved compound instead of evidence-based care carries its own substantial risk

Drug & supplement interactions

S
e
l
t
o
r
e
x
a
n
t
i
s
m
e
t
a
b
o
l
i
z
e
d
s
u
b
s
t
a
n
t
i
a
l
l
y
b
y
C
Y
P
3
A
4
,
s
o
c
o
-
a
d
m
i
n
i
s
t
r
a
t
i
o
n
w
i
t
h
s
t
r
o
n
g
C
Y
P
3
A
4
i
n
h
i
b
i
t
o
r
s
(
f
o
r
e
x
a
m
p
l
e
c
e
r
t
a
i
n
a
z
o
l
e
a
n
t
i
f
u
n
g
a
l
s
,
m
a
c
r
o
l
i
d
e
a
n
t
i
b
i
o
t
i
c
s
,
a
n
d
s
o
m
e
p
r
o
t
e
a
s
e
i
n
h
i
b
i
t
o
r
s
)
w
o
u
l
d
b
e
e
x
p
e
c
t
e
d
t
o
r
a
i
s
e
i
t
s
e
x
p
o
s
u
r
e
,
w
h
i
l
e
s
t
r
o
n
g
C
Y
P
3
A
4
i
n
d
u
c
e
r
s
c
o
u
l
d
l
o
w
e
r
i
t
.
A
s
a
s
e
d
a
t
i
n
g
,
s
l
e
e
p
-
p
r
o
m
o
t
i
n
g
a
g
e
n
t
i
t
h
a
s
a
d
d
i
t
i
v
e
C
N
S
-
d
e
p
r
e
s
s
a
n
t
p
o
t
e
n
t
i
a
l
w
i
t
h
a
l
c
o
h
o
l
,
b
e
n
z
o
d
i
a
z
e
p
i
n
e
s
,
o
p
i
o
i
d
s
,
s
e
d
a
t
i
n
g
a
n
t
i
h
i
s
t
a
m
i
n
e
s
,
a
n
d
o
t
h
e
r
h
y
p
n
o
t
i
c
s
,
i
n
c
r
e
a
s
i
n
g
r
i
s
k
o
f
e
x
c
e
s
s
i
v
e
s
e
d
a
t
i
o
n
a
n
d
n
e
x
t
-
d
a
y
i
m
p
a
i
r
m
e
n
t
.
B
e
c
a
u
s
e
t
r
i
a
l
u
s
e
h
a
s
b
e
e
n
a
s
a
n
a
d
d
-
o
n
t
o
S
S
R
I
s
/
S
N
R
I
s
,
i
t
s
i
n
t
e
r
a
c
t
i
o
n
p
r
o
f
i
l
e
w
i
t
h
t
h
e
b
r
o
a
d
e
r
r
a
n
g
e
o
f
p
s
y
c
h
o
t
r
o
p
i
c
s
a
n
d
e
v
e
r
y
d
a
y
m
e
d
i
c
a
t
i
o
n
s
o
u
t
s
i
d
e
t
r
i
a
l
s
e
t
t
i
n
g
s
i
s
n
o
t
f
u
l
l
y
c
h
a
r
a
c
t
e
r
i
z
e
d
.
N
o
n
e
o
f
t
h
i
s
c
o
n
s
t
i
t
u
t
e
s
c
l
e
a
r
a
n
c
e
t
o
c
o
m
b
i
n
e
i
t
w
i
t
h
a
n
y
t
h
i
n
g
;
i
t
u
n
d
e
r
s
c
o
r
e
s
t
h
a
t
o
n
l
y
a
c
l
i
n
i
c
i
a
n
w
i
t
h
a
f
u
l
l
m
e
d
i
c
a
t
i
o
n
l
i
s
t
c
a
n
a
s
s
e
s
s
i
n
t
e
r
a
c
t
i
o
n
r
i
s
k
.

Who should avoid it

Anyone not enrolled in a legitimate, supervised clinical trial (there is no lawful consumer route to this investigational drug)
People seeking to self-treat depression or insomnia in place of evidence-based, clinician-directed care
Individuals taking strong CYP3A4 inhibitors or inducers, given the CYP3A4-dependent metabolism
People who drink alcohol at bedtime or take other CNS depressants or sedative-hypnotics
Anyone who must drive or operate machinery in the hours after dosing, due to sedation and possible next-day impairment
Pregnant or breastfeeding individuals, for whom safety has not been established

How it is commonly combined

This reference does not endorse stacking an unapproved investigational drug. In its clinical development seltorexant has been deliberately studied as an add-on ('stack') to an existing SSRI or SNRI antidepressant in patients with residual insomnia, which is a supervised, trial-defined combination rather than a self-directed one. Layering seltorexant with other sedatives, alcohol, or additional serotonergic or CNS-active agents outside a trial adds sedation and interaction risk without any evidence of benefit and is not advisable. Any legitimate combination decision belongs to a treating clinician.

Legal & regulatory. Seltorexant is an investigational new drug in the United States. It is not FDA-approved for any indication, and it is not a dietary supplement, a food, or a lawful over-the-counter product. It exists only within sponsor-run clinical trials run by Johnson and Johnson (Janssen), with Minerva Neurosciences as a co-developer. There is no legal channel for a consumer to obtain it outside of a trial, and any material sold online as "seltorexant" by a gray-market research-chemical vendor is unverified, outside the regulatory chain of custody, and not approved for human consumption. Unlike the approved dual orexin antagonists suvorexant, lemborexant, and daridorexant, seltorexant carries no prescribing status.

Quality & harm reduction

Safer, legal alternative we recommend

Sleepio Formula. For the same sleep goal, our Sleep Formula is a legal, non-prescription option you can buy now.

See our recommended pick

Find Seltorexant →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is seltorexant FDA-approved or available by prescription?

No. As of this writing it is an investigational drug that has not been approved by the FDA for any indication and is not available by prescription. It exists only within sponsor-run clinical trials. The approved orexin sleep drugs are different molecules (suvorexant, lemborexant, daridorexant).

How is seltorexant different from suvorexant or daridorexant?

Those approved insomnia drugs are dual orexin receptor antagonists (DORAs) that block both OX1 and OX2. Seltorexant is a selective OX2 antagonist (2-SORA) with reported greater than 100-fold selectivity for OX2, and it is being developed chiefly for depression with insomnia rather than as a standalone hypnotic.

Does the evidence show it treats depression?

The data are mixed. A placebo-controlled Phase 3 study reported a statistically significant improvement in depression scores when seltorexant was added to an antidepressant. But a separate Phase 3 study comparing it head-to-head against quetiapine XR did not meet its primary endpoint. The signal appears real but modest and design-dependent, and it is not an approved treatment.

What dose is used in studies?

This is informational only and not dosing advice. Trials have commonly used a single oral bedtime dose, with 20 mg once nightly prominent in the Phase 3 MDD-with-insomnia program. These are supervised trial conditions and do not translate to any product sold to consumers. Talk to a clinician about approved options rather than self-dosing.

Is 'seltorexant' sold as a research chemical trustworthy?

No. There is no legitimate consumer supply. Any powder or capsule sold to individuals is outside the pharmaceutical chain of custody, and its identity, purity, and dose cannot be verified. Vendor certificates of analysis are not independently verifiable.

What are the main reported side effects?

In trials the more commonly reported effects have included somnolence, fatigue, dizziness, headache, abdominal discomfort, and nightmares or abnormal dreams. As a sedating agent it can impair next-day alertness and driving, and its long-term safety in the general population is not established.

References & further reading

PubMed: seltorexant JNJ-42847922 MIN-202 major depressive disorder antidepressant sleep
PubMed: seltorexant orexin-2 receptor antagonist insomnia efficacy safety
ClinicalTrials.gov: seltorexant adjunctive antidepressant major depressive disorder insomnia phase 3
ClinicalTrials.gov: seltorexant quetiapine XR MDD3005 comparator
PubMed: selective orexin-2 antagonist 2-SORA pharmacokinetics CYP3A4 half-life